Malignant hyperthermia: A pharmacogenetic disorder

Pharmacogenomics

Volumn 9, Issue 11, 2008, Pages 1657-1672

  Stowell, Kathryn M ^a  

^a MASSEY UNIVERSITY   (New Zealand)

Author keywords

anesthesia; calcium homeostasis; genotypephenotype; malignant hyperthermia; ryanodine receptor; skeletal muscle

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; DANTROLENE; INHALATION ANESTHETIC AGENT; MUSCLE RELAXANT AGENT; RYANODINE RECEPTOR; RYANODINE RECEPTOR 1; CALCIUM; CENTRAL MUSCLE RELAXANT;

CALCIUM HOMEOSTASIS; CLINICAL FEATURE; EXCITATION CONTRACTION COUPLING; EXERCISE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MALIGNANT HYPERTHERMIA; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENETICS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STRESS; ANIMAL; GENETICS; HEART MUSCLE; METABOLISM;

ANIMALS; CALCIUM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE RELAXANTS, CENTRAL; MUSCLE, SKELETAL; MYOCARDIUM; PHARMACOGENETICS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 61549106950     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.11.1657     Document Type: Review

References (130)

1. Denborough M, Lovell R: Anaesthetic deaths in a family. Lancet 2, 45 (1960).
2. Ruffert H, Olthoff D, Deutrich C, Froster UG: Current aspects of the diagnosis of malignant hyperthermia. Anaesthesist 51, 904-913 (2002). (Pubitemid 35430630)
3. Girard T, Treves S, Voronkov E, Siegemund M, Urwyler A: Molecular genetic testing for malignant hyperthermia susceptibility. Anesthesiology 100, 1076-1080 (2004). (Pubitemid 38541961)
4. Robinson RL, Anetseder MJ, Brancadoro V, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur. J. Hum. Genet. 11, 342-348 (2003). (Pubitemid 36553493)
5. MacLennan DH, Chen SR: The role of the calcium release channel of skeletal muscle sarcoplasmic reticulum in malignant hyperthermia. Ann. NY Acad. Sci. 707, 294-304 (1993). (Pubitemid 24099485)
6. Britt BA, Kalow W: Malignant hyperthermia: a statistical review. Can. Anaesth. Soc. J. 17, 293-315 (1970).
7. Robinson RL, Curran JL, Ellis FR, et al. Multiple interacting gene products may influence susceptibility to malignant hyperthermia. Ann. Hum. Genet. 64, 307-320 (2000).
8. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P: Mutations in RYR1 in malignant hyperthermia and central core disease. Hum. Mutat. 27, 977-989 (2006). (Pubitemid 44454050)
9. Ibarra MC, Wu S, Murayama K, et al. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology 104, 1146-1154 (2006). (Pubitemid 43852946)
10. Monnier N, Krivosic-Horber R, Payen JF, et al. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 97, 1067-1074. (2002). (Pubitemid 35265557)
11. MacLennan DH, Phillips MS: Malignant hyperthermia. Science 256, 789-794 (1992).
12. Heffron JJA: Malignant hyperthermia: biochemical aspects of the acute episode. Br. J. Anaesth. 60, 274-278 (1988).
13. Flucher BE, Andrews SB, Fleischer S, Marks AR, Caswell A, Powell JA: Triad formation: organization and function of the sarcoplasmic reticulum calcium release channel and triadin in normal and dysgenic muscle in vitro. J. Cell Biol. 123, 1161-1174 (1993). (Pubitemid 23352425)
14. Denborough M: Malignant hyperthermia. Lancet 352, 1131-1136 (1998). (Pubitemid 28448529)
15. Fruen BR, Mickelson JR, Louis CF: Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. J. Biol. Chem. 272, 26965-26971 (1997).
16. Rosenberg H, Davis M, James D, Pollock N, Stowell K: Malignant hyperthermia. Orphanet. J. Rare Dis. 2, 21 (2007). (Pubitemid 38949994)
17. Brown RL, Pollock AN, Couchman KG, et al. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. Human Molecular Genetics 9, 1515-1524 (2000).
18. Gronert GA, Thompson RL, Onofrio BM: Human malignant hyperthermia: awake episodes and correction by dantrolene. Anesth. Analg. 59, 377-378 (1980).
19. Wappler F, Fiege M, Steinfath M, et al. Evidence for susceptibility to malignant hyperthermia in patients with exerciseinduced rhabdomyolysis. Anesthesiology 94, 95-100 (2001). (Pubitemid 32055184)
20. Davis M, Brown R, Dickson A, et al. Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. Br. J. Anaesth. 88, 508-515 (2002). (Pubitemid 34285200)
21. Wappler F, Fiege M, Antz M, Schulte am Esch J: Hemodynamic and metabolic alterations in response to graded exercise in a patient susceptible to malignant hyperthermia. Anesthesiology 92, 268-272 (2000). (Pubitemid 30027475)
22. Bellinger AM, Reiken S, Dura M, et al. Remodeling of ryanodine receptor complex causes leaky channels: a molecular mechanism for decreased exercise capacity. Proc. Natl Acad. Sci. USA 105, 2198-2202 (2008). (Pubitemid 351439488)
23. Avila G, Lee EH, Perez CF, Allen PD, Dirksen RT: FKBP12 binding to RyR1 modulates excitation-contraction coupling in mouse skeletal myotubes. J. Biol. Chem. 278, 22600-22608 (2003). (Pubitemid 36830317)
24. Larach MG: Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth. Analg. 69, 511-515 (1989).
25. Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European Group MH: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol. Scand. 41, 955-966 (1997). (Pubitemid 27414735)
26. Urwyler A, Deufel T, McCarthy T, West S: Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br. J. Anaesth. 86, 283-287. (2001). (Pubitemid 32103424)
27. MacLennan DH, Duff C, Zorzato F, et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 343, 559-561 (1990). (Pubitemid 20042716)
28. McCarthy TV, Healy JM, Heffron JJ, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 343, 562-564 (1990). (Pubitemid 20042717)
29. Monnier N, Procaccio V, Stieglitz P, Lunardi J: malignant-hyperthermia susceptibility is associated with a mutation of the 1-subunit of the human dihydropyridine-sensitive l-type voltagedependent calcium-channel receptor in skeletal muscle. Am. J. Hum. Genet. 60, 1316-1325 (1997). (Pubitemid 27258063)
30. Monnier N, Kozak-Ribbens G, Krivosic-Horber R, et al. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum. Mutat. 26, 413-425 (2005). (Pubitemid 41572448)
31. Priori SG, Napolitano C: Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels. J. Clin. Invest. 115, 2033-2038 (2005). (Pubitemid 41134139)
32. Weiss RG, OConnell KM, Flucher BE, Allen PD, Grabner M, Dirksen RT: Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. Am. J. Physiol. Cell Physiol. 287, C1094-C1102 (2004). (Pubitemid 39238334)
33. Urwyler A, Halsall PJ, Mueller C, Robinson R: Ryanodine receptor gene (RYR1) mutations for diagnosing susceptibility to malignant hyperthermia. Acta Anaesthesiol. Scand. 47, 492; author reply 493 (2003). (Pubitemid 36438871)
34. Allen GC, Larach MG, Kunselman AR: The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 88, 579-588 (1998).
35. Fleischer S: Personal recollections on the discovery of the ryanodine receptors of muscle. Biochem. Biophys. Res. Commun. 369, 195-207 (2008).
36. Nakai J, Dirksen RT, Nguyen HT, Pessah IN, Beam KG, Allen PD: Enhanced dihydropyridine receptor channel activity in the presence of ryanodine receptor. Nature 380, 72-75 (1996). (Pubitemid 26076239)
37. Nakai J, Sekiguchi N, Rando TA, Allen PD, Beam KG: Two regions of the ryanodine receptor involved in coupling with l-type Ca2+ channels. J. Biol. Chem. 273, 13403-13406 (1998). (Pubitemid 28268377)
38. Serysheva II: Structural insights into excitation-contraction coupling by electron cryomicroscopy. Biochemistry (Mosc.) 69, 1226-1232 (2004).
39. Samso M, Shen X, Allen PD: Structural characterization of the RyR1-FKBP12 interaction. J. Mol. Biol. 356, 917-927 (2006). (Pubitemid 43145946)
40. Paolini C, Protasi F, Franzini-Armstrong C: The relative position of RyR feet and DHPR tetrads in skeletal muscle. J. Mol. Biol. 342, 145-153 (2004). (Pubitemid 39094511)
41. Lyfenko AD, Goonasekera SA, Dirksen RT: Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease. Biochem. Biophys. Res. Commun. 322, 1256-1266 (2004).
42. Gerasimenko JV, Maruyama Y, Yano K, et al. NAADP mobilizes Ca2+ from a thapsigarginsensitive store in the nuclear envelope by activating ryanodine receptors. J. Cell Biol. 163, 271-282 (2003). (Pubitemid 37363128)
43. Meissner G, Lu X: Dihydropyridine receptor-ryanodine receptor interactions in skeletal muscle excitation-contraction coupling. Biosci. Rep. 15, 399-408 (1995). (Pubitemid 26050858)
44. Ikemoto N, Yamamoto T: Regulation of calcium release by interdomain interaction within ryanodine receptors. Front Biosci. 7, D671-D683 (2002).
45. Protasi F, Paolini C, Nakai J, Beam KG, Franzini-Armstrong C, Allen PD: Multiple regions of RyR1 mediate functional and structural interactions with a(1S)-dihydropyridine receptors in skeletal muscle. Biophys. J. 83, 3230-3244 (2002). (Pubitemid 36041942)
46. Brini M: Ryanodine receptor defects in muscle genetic diseases. Biochem. Biophys. Res. Commun. 322, 1245-1255 (2004). (Pubitemid 39164654)
47. MacLennan DH: Ca2+ signalling and muscle disease. Eur. J. Biochem. 267, 5291-5297 (2000).
48. Gommans IM, Vlak MH, de Haan A, van Engelen BG: Calcium regulation and muscle disease. J. Muscle Res. Cell Motil. 23, 59-63 (2002).
49. Cahalan MD, Zhang SL, Yeromin AV, Ohlsen K, Roos J, Stauderman KA: Molecular basis of the CRAC channel. Cell Calcium 42, 133-144 (2007). (Pubitemid 47029601)
50. Gonzalez Narvaez AA, Castillo A: Ca2+ store determines gating of store operated calcium entry in mammalian skeletal muscle. J. Muscle Res. Cell Motil. 28, 105-113 (2007). (Pubitemid 47434725)
51. Ma J, Pan Z: Junctional membrane structure and store operated calcium entry in muscle cells. Front Biosci. 8, D242-D255 (2003). (Pubitemid 39069975)
52. Thompson M, White T, Chini EN: Modulation of store-operated Ca2+ entry by cyclic-ADP-ribose. Braz. J. Med. Biol. Res. 39, 739-748 (2006). (Pubitemid 43880931)
53. Weigl L, Zidar A, Gscheidlinger R, Karel A, Hohenegger M: Store operated Ca2+ influx by selective depletion of ryanodine sensitive Ca2+ pools in primary human skeletal muscle cells. Naunyn Schmiedebergs Arch. Pharmacol. 367, 353-363 (2003). (Pubitemid 36535303)
54. Kurebayashi N, Ogawa Y: Depletion of Ca2+ in the sarcoplasmic reticulum stimulates Ca2+ entry into mouse skeletal muscle fibres. J. Physiol. 533, 185-199 (2001). (Pubitemid 32499371)
55. Launikonis BS, Barnes M, Stephenson DG: Identification of the coupling between skeletal muscle store-operated Ca2+ entry and the inositol trisphosphate receptor. Proc. Natl. Acad. Sci. USA 100, 2941-2944 (2003). (Pubitemid 36297602)
56. Roos J, DiGregorio PJ, Yeromin AV, et al. STIM1, an essential and conserved component of store-operated Ca2+ channel function. J. Cell Biol. 169, 435-445 (2005). (Pubitemid 40686694)
57. Zhang SL, Yu Y, Roos J, et al. STIM1 is a Ca2+ sensor that activates CRAC channels and migrates from the Ca2+ store to the plasma membrane. Nature 437, 902-905 (2005). (Pubitemid 41486767)
58. Lee EH, Cherednichenko G, Pessah IN, Allen PD: Functional coupling between TRPC3 and RyR1 regulates the expressions of key triadic proteins. J. Biol. Chem. 281, 10042-10048 (2006). (Pubitemid 43864538)
59. Santillan G, Katz S, Vazquez G, Boland RL: TRPC3-like protein and vitamin D receptor mediate 1a,25(OH)2D3-induced SOC influx in muscle cells. Int. J. Biochem. Cell Biol. 36, 1910-1918 (2004).
60. Treves S, Franzini-Armstrong C, Moccagatta L, et al. Junctate is a key element in calcium entry induced by activation of InsP3 receptors and/or calcium store depletion. J. Cell Biol. 166, 537-548 (2004). (Pubitemid 39097173)
61. Sampieri A, Diaz-Munoz M, Antaramian A, Vaca L: The foot structure from the type 1 ryanodine receptor is required for functional coupling to store-operated channels. J. Biol. Chem. 280, 24804-24815 (2005). (Pubitemid 40934571)
62. Stiber J, Hawkins A, Zhang ZS, et al. STIM1 signalling controls store-operated calcium entry required for development and contractile function in skeletal muscle. Nat. Cell Biol. 10, 688-697 (2008). (Pubitemid 351772934)
63. Cherednichenko G, Hurne AM, Fessenden JD, et al. Conformational activation of Ca2+ entry by depolarization of skeletal myotubes. Proc. Natl. Acad. Sci. USA 101, 15793-15798 (2004). (Pubitemid 39473567)
64. Murayama T, Ogawa Y: RyR1 exhibits lower gain of CICR activity than RyR3 in the SR: evidence for selective stabilization of RyR1 channel. Am. J. Physiol. Cell Physiol. 287, C36-C45 (2004). (Pubitemid 38780150)
65. Anderson AA, Brown RL, Polster B, Pollock N, Stowell KM: Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia. Anesthesiology 108, 208-215 (2008). (Pubitemid 351156730)
66. Sei Y, Brandom BW, Bina S, et al. Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes. Anesthesiology 97, 1052-1058 (2002). (Pubitemid 35265555)
67. Tong J, Oyamada H, Demaurex N, Grinstein S, McCarthy TV, MacLennan DH: Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J. Biol. Chem. 272, 26332-26339 (1997). (Pubitemid 27458847)
68. Herrmann-Frank A, Richter M, Sarkozi S, Mohr U, Lehmann-Horn F: 4chloromcresol, a potent and specific activator of the skeletal muscle ryanodine receptor. Biochim. Biophys. Acta. 1289, 31-40 (1996). (Pubitemid 26075668)
69. Diaz-Sylvester PL, Porta M, Copello JA: Halothane modulation of skeletal muscle ryanodine receptors: dependence on Ca2+, Mg2+, and ATP. Am. J. Physiol. Cell Physiol. 294, C1103-C1112 (2008). (Pubitemid 351507910)
70. Zhao X, Weisleder N, Han X, et al. Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. J. Biol. Chem. 281, 33477-33486 (2006). (Pubitemid 46036729)
71. Yang T, Ta TA, Pessah IN, Allen PD: Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. J. Biol. Chem. 278, 25722-25730 (2003). (Pubitemid 36835328)
72. Kobayashi S, Yamamoto T, Parness J, Ikemoto N: Antibody probe study of Ca2+ channel regulation by interdomain interaction within the ryanodine receptor. Biochem. J. 380, 561-569 (2004). (Pubitemid 38788128)
73. Kobayashi S, Bannister ML, Gangopadhyay JP, Hamada T, Parness J, Ikemoto N: Dantrolene stabilizes domain interactions within the ryanodine receptor. J. Biol. Chem. 280, 6580-6587 (2005). (Pubitemid 40341208)
74. Dulhunty AF, Beard NA, Pouliquin P, Kimura T: Novel regulators of RyR Ca2+ release channels: insight into molecular changes in genetically-linked myopathies. J. Muscle Res. Cell Motil. 27, 351-365 (2006). (Pubitemid 44325614)
75. Oyamada H, Oguchi K, Saitoh N, et al. Novel mutations in C-terminal channel region of the ryanodine receptor in malignant hyperthermia patients. Jpn. J. Pharmacol. 88, 159-166 (2002). (Pubitemid 34223565)
76. Loke JC, Kraev N, Sharma P, et al. Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript. Anesthesiology 99, 297-302 (2003). (Pubitemid 36909555)
77. Querfurth HW, Haughey NJ, Greenway SC, Yacono PW, Golan DE, Geiger JD: Expression of ryanodine receptors in human embryonic kidney (HEK293) cells. Biochem. J. 334 (Pt 1), 79-86 (1998). (Pubitemid 28420974)
78. Bhat MB, Zhao J, Zang W, et al. Caffeine-induced release of intracellular Ca2+ from Chinese hamster ovary cells expressing skeletal muscle ryanodine receptor. Effects on full-length and carboxyl-terminal portion of Ca2+ release channels. J. Gen. Physiol. 110, 749-762 (1997). (Pubitemid 27524613)
79. Tilgen N, Zorzato F, Halliger-Keller B, et al. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Hum. Mol. Genet. 10, 2879-2887 (2001). (Pubitemid 34030919)
80. Wehner M, Rueffert H, Koenig F, Olthoff D: Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala. Genet. Test. 7, 203-211 (2003). (Pubitemid 37363079)
81. Wehner M, Rueffert H, Koenig F, Neuhaus J, Olthoff D: Increased sensitivity to 4′chloromcresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation. Clin. Genet. 62, 135-146 (2002). (Pubitemid 36372713)
82. OSullivan GH, McIntosh JM, Heffron JJ: Abnormal uptake and release of Ca2+ ions from human malignant hyperthermiasusceptible sarcoplasmic reticulum. Biochem. Pharmacol. 61, 1479-1485 (2001).
83. Shtifman A, Ward CW, Yamamoto T, et al. Interdomain interactions within ryanodine receptors regulate Ca(2)+ spark frequency in skeletal muscle. J. Gen. Physiol. 119, 15-32 (2002). (Pubitemid 34074590)
84. Girard T, Treves S, Censier K, Mueller CR, Zorzato F, Urwyler A: Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells. Br. J. Anaesth. 89, 571-579 (2002). (Pubitemid 35153779)
85. Chelu MG, Goonasekera SA, Durham WJ, et al. Heat-and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. Faseb. J. 20, 329-330 (2006).
86. Yang T, Riehl J, Esteve E, et al. Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse. Anesthesiology 105, 1164-1175 (2006). (Pubitemid 44808580)
87. Ogawa Y: Distinct mechanisms for dysfunctions of mutated ryanodine receptor isoforms. Biochem. Biophys. Res. Commun. 369, 208-212 (2008).
88. Brini M, Manni S, Pierobon N, et al. Ca2+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations. J. Biol. Chem. 280, 15380-15389 (2005). (Pubitemid 40562895)
89. Tong J, McCarthy TV, MacLennan DH: Measurement of resting cytosolic Ca2+ concentrations and Ca2+ store size in HEK-293 cells transfected with malignant hyperthermia or central core disease mutant Ca2+ release channels. J. Biol. Chem. 274, 693-702 (1999). (Pubitemid 129535224)
90. Du GG, Oyamada H, Khanna VK, MacLennan DH: Mutations to Gly2370, Gly2373 or Gly2375 in malignant hyperthermia domain 2 decrease caffeine and cresol sensitivity of the rabbit skeletal-muscle Ca2+-release channel (ryanodine receptor isoform 1). Biochem. J. 360, 97-105. (2001). (Pubitemid 33081953)
91. Treves S, Larini F, Menegazzi P, et al. Alteration of intracellular Ca2+ transients in COS7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia. Biochem. J. 301, 661-665 (1994). (Pubitemid 2118776)
92. Sei Y, Gallagher KL, Daly JW: Multiple effects of caffeine on Ca2+ release and influx in human B lymphocytes. Cell Calcium 29, 149-160 (2001). (Pubitemid 32184386)
93. Steele DS, Duke AM: Defective Mg(2+) regulation of RyR1 as a causal factor in malignant hyperthermia. Arch. Biochem. Biophys. 458, 57-64 (2007).
94. Paul-Pletzer K, Yamamoto T, Bhat MB, et al. Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J. Biol. Chem. 277, 34918-34923 (2002).
95. Cherednichenko G, Ward CW, Feng W, et al. Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene. Mol. Pharmacol. 73, 1203-1212 (2008). (Pubitemid 351439202)
96. Dulhunty AF: Excitation-contraction coupling from the 1950s into the new millennium. Clin. Exp. Pharmacol. Physiol. 33, 763-772 (2006).
97. Bannister ML, Ikemoto N: Effects of peptide C corresponding to the Glu724′Pro760 region of the II-III loop of the DHP (dihydropyridine) receptor a1 subunit on the domain-switch-mediated activation of RyR1 (ryanodine receptor 1) Ca2+ channels. Biochem. J. 394, 145-152 (2006). (Pubitemid 43259664)
98. Bannister ML, Hamada T, Murayama T, et al. Malignant hyperthermia mutation sites in the Leu2442-Pro2477 (DP4) region of RyR1 (ryanodine receptor 1) are clustered in a structurally and functionally definable area. Biochem. J. 401, 333-339 (2007). (Pubitemid 46114626)
99. Haarmann CS, Dulhunty AF, Laver DR: Regulation of skeletal ryanodine receptors by dihydropyridine receptor II-III loop C-region peptides: relief of Mg2+ inhibition. Biochem. J. 387, 429-436 (2005).
100. Bannister RA, Grabner M, Beam KG: The 1S III-IV loop influences 1,4′dihydropyridine receptor gating but is not directly involved in excitation-contraction coupling interactions with the type 1 ryanodine receptor. J. Biol. Chem. 283, 23217-23223 (2008).
101. Lopez JR, Linares N, Pessah IN, Allen PD: Enhanced response to caffeine and 4′chloromcresol in malignant hyperthermiasusceptible muscle is related in part to chronically elevated resting [Ca2+]i. Am. J. Physiol. Cell Physiol. 288, C606-12 (2005). (Pubitemid 40229489)
102. Avila G, Dirksen RT: Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor. J. Gen. Physiol. 118, 277-290 (2001). (Pubitemid 32845963)
103. Yang T, Esteve E, Pessah IN, Molinski TF, Allen PD, Lopez JR: Elevated resting [Ca(2+)] (i) in myotubes expressing malignant hyperthermia RyR1 cDNAs is partially restored by modulation of passive calcium leak from the SR. Am. J. Physiol. Cell Physiol. 292, C1591-C1598 (2007). (Pubitemid 47080573)
104. Murayama T, Oba T, Hara H, Wakebe K, Ikemoto N, Ogawa Y: Postulated role of interdomain interaction between regions 1 and within type 1 ryanodine receptor in the pathogenesis of porcine malignant hyperthermia. Biochem. J. 402, 349-357 (2007). (Pubitemid 46383432)
105. Bleunven C, Treves S, Jinyu X, et al. SRP-27 is a novel component of the supramolecular signalling complex involved in skeletal muscle excitation-contraction coupling. Biochem. J. 411, 343-349 (2008). (Pubitemid 351580186)
106. Divet A, Paesante S, Bleunven C, Anderson A, Treves S, Zorzato F: Novel sarco(endo)plasmic reticulum proteins and calcium homeostasis in striated muscles. J. Muscle Res. Cell Motil. 26, 7-12 (2005). (Pubitemid 41531494)
107. Gouadon E, Schuhmeier RP, Ursu D, et al. A possible role of the junctional face protein JP45 in modulating Ca2+ release in skeletal muscle. J. Physiol. 572, 269-280 (2006).
108. Zhang M, Yamazaki T, Yazawa M, et al. Calumin, a novel Ca2+-binding transmembrane protein on the endoplasmic reticulum. Cell Calcium 42, 83-90 (2007). (Pubitemid 46760456)
109. Woo JS, Kim do H, Allen PD, Lee EH: TRPC3-interacting triadic proteins in skeletal muscle. Biochem. J. 411, 399-405 (2008).
110. Pan Z, Hirata Y, Nagaraj RY, et al. Co-expression of MG29 and ryanodine receptor leads to apoptotic cell death: effect mediated by intracellular Ca2+ release. J. Biol. Chem. 279, 19387-19390 (2004). (Pubitemid 38623370)
111. Pan Z, Yang D, Nagaraj RY, et al. Dysfunction of store-operated calcium channel in muscle cells lacking mg29. Nat. Cell Biol. 4, 379-383 (2002). (Pubitemid 34521034)
112. Goonasekera SA, Beard NA, Groom L, et al. Triadin binding to the C-terminal luminal loop of the ryanodine receptor is important for skeletal muscle excitation contraction coupling. J. Gen. Physiol. 130, 365-378 (2007). (Pubitemid 47481600)
113. Vassilopoulos S, Brocard J, Garcia L, Marty I, Bouron A: Retrograde regulation of storeoperated calcium channels by the ryanodine receptor-associated protein triadin 95 in rat skeletal myotubes. Cell Calcium 41, 179-185 (2007). (Pubitemid 44964460)
114. Divet A, Paesante S, Grasso C, et al. Increased Ca2+ storage capacity of the skeletal muscle sarcoplasmic reticulum of transgenic mice over-expressing membrane bound calcium binding protein junctate. J. Cell Physiol. 213, 464-474 (2007). (Pubitemid 47509728)
115. Anderson AA, Altafaj X, Zheng Z, et al. The junctional SR protein JP-45 affects the functional expression of the voltage-dependent Ca2+ channel Cav1.1. J. Cell Sci. 119, 2145-2155 (2006). (Pubitemid 43904969)
116. Delbono O, Xia J, Treves S, et al. Loss of skeletal muscle strength by ablation of the sarcoplasmic reticulum protein JP45. Proc. Natl Acad. Sci. USA 104, 20108-20113 (2007).
117. Jungbluth H: Central core disease. Orphanet. J. Rare Dis. 2, 25 (2007).
118. Du GG, Khanna VK, Guo X, MacLennan DH: Central core disease mutations R4892W, I4897T and G4898E in the ryanodine receptor isoform 1 reduce the Ca2+ sensitivity and amplitude of Ca2+-dependent Ca2+ release. Biochem. J. 382, 557-564 (2004). (Pubitemid 39243922)
119. Lyfenko AD, Ducreux S, Wang Y, et al. Two central core disease (CCD) deletions in the C-terminal region of RYR1 alter muscle excitation-contraction (EC) coupling by distinct mechanisms. Hum. Mutat. 28, 61-68 (2007). (Pubitemid 46036214)
120. Zvaritch E, Depreux F, Kraeva N, et al. An Ryr1I4895T mutation abolishes Ca2+ release channel function and delays development in homozygous offspring of a mutant mouse line. Proc. Natl Acad. Sci. USA 104, 18537-18542 (2007). (Pubitemid 350210732)
121. Zhou H, Yamaguchi N, Xu L, et al. Characterization of recessive RYR1 mutations in core myopathies. Hum. Mol. Genet. 15, 2791-2803 (2006). (Pubitemid 44400406)
122. Zhou H, Brockington M, Jungbluth H, et al. Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies. Am. J. Hum. Genet. 79, 859-868 (2006). (Pubitemid 44763400)
123. Girard T, Cavagna D, Padovan E, et al. B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. J. Biol. Chem. 276, 48077-48082 (2001). (Pubitemid 37370709)
124. McKinney LC, Butler T, Mullen SP, Klein MG: Characterization of ryanodine receptor-mediated calcium release in human B cells: relevance to diagnostic testing for malignant hyperthermia. Anesthesiology 104, 1191-1201 (2006). (Pubitemid 43852952)
125. Sambuughin N, Nelson TE, Jankovic J, et al. Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families. Neuromuscul. Disord. 11, 530-537 (2001). (Pubitemid 32761795)
126. Wehner M, Rueffert H, Koenig F, Olthoff D: Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model. Neuromuscul. Disord. 14, 429-437 (2004). (Pubitemid 38798261)
127. Wehner M, Rueffert H, Koenig F, Meinecke CD, Olthoff D: The Ile2453Thr mutation in the ryanodine receptor gene 1 is associated with facilitated calcium release from sarcoplasmic reticulum by 4′chloromcresol in human myotubes. Cell Calcium 34, 163-168 (2003). (Pubitemid 36798399)
128. Monnier N, Romero NB, Lerale J, et al. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. Hum. Mol. Genet. 9, 2599-2608 (2000).
129. Yang T, Allen PD, Pessah IN, Lopez JR: Enhanced excitation-coupled calcium entry in myotubes is associated with expression of RYR1 malignant hyperthermia mutations. J. Biol. Chem. 282, 37471-37478 (2007).
130. European malignant hyperthermia group www.emhg.org